EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine

Matthew P Kosloski iD, Hong Li, Stanley Wang, Federico Mensa, Jens Kort, Wei Liu

Clinical and Translational Science · 2023-04 · 16 (4) · 593-605

DOI: 10.1111/cts.13471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 23.01.2023. Verfasst von Matthew P Kosloski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Organic Anion Transporters. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The fixed‐dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once‐daily treatment for all six major genotypes of chronic hepatitis C virus infection. A single and multiple‐dose rifampin study ( N = 12) and a carbamazepine study ( N = 12) were conducted in healthy subjects to evaluate the effects of CYP3A/P‐gp induction and OATP inhibition on the pharmacokinetics of GLE and PIB. In study 1, GLE 300 mg + PIB 120 mg was administered as a single dose either alone, after single and multiple daily doses of rifampin 600 mg, or 24 h after the last rifampin dose. In study 2, GLE 300 mg + PIB 120 mg was administered as a single dose either alone or after multiple doses of carbamazepine 200 mg. Relative to GLE + PIB alone, exposure of GLE was significantly increased by the first co‐administered rifampin dose due to OATP inhibition, significantly decreased 24 h after the last rifampin dose due to CYP3A/P‐gp induction, and slightly increased when co‐administered with steady‐state rifampin due to a combination of inhibition and induction forces. Exposure of PIB was not affected when co‐administered with the first rifampin dose but was significantly decreased with steady‐state rifampin co‐administration, or 24 h after the last rifampin dose due to P‐gp induction. Carbamazepine significantly decreased GLE and PIB exposure, mainly attributed to P‐gp induction. The regimens tested were generally well‐tolerated by the subjects and no new safety issues were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicOrganic Anion TransportersHumansAntiviral AgentsRifampinCytochrome P-450 CYP3ADrug InteractionsHepacivirusGenotypeBenzimidazolesPyrrolidinesDrug CombinationsQuinoxalinesAminoisobutyric AcidsCyclopropanesLeucineProlineSulfonamidesLactams, Macrocyclic

Substanzen

Antiviral AgentsRifampinCytochrome P-450 CYP3AOrganic Anion TransporterspibrentasvirBenzimidazolesPyrrolidinesglecaprevir and pibrentasvirDrug CombinationsQuinoxalines

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
  • Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois, USA.
  • Infectious Disease, AbbVie Inc., North Chicago, Illinois, USA.
  • Medical Affairs, AbbVie Inc., North Chicago, Illinois, USA.

ORCID-Profile: Matthew P Kosloski

Zitieren

APA

Kosloski, M. P., Li, H., Wang, S., Mensa, F., Kort, J., & Liu, W. (2023). Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine. Clinical and Translational Science, 16(4), 593-605. https://doi.org/10.1111/cts.13471

Vancouver

Kosloski MP, Li H, Wang S, Mensa F, Kort J, Liu W. Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine. Clinical and Translational Science. 2023;16(4):593-605. doi:10.1111/cts.13471

BibTeX
@article{Kosloski2023,
  author = {Kosloski, Matthew P and Li, Hong and Wang, Stanley and Mensa, Federico and Kort, Jens and Liu, Wei},
  title = {Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine},
  journal = {Clinical and Translational Science},
  year = {2023},
  volume = {16},
  number = {4},
  pages = {593--605},
  doi = {10.1111/cts.13471}
}
Kostenlos starten →